<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Agree Realty Corporation</title>
	<atom:link href="http://www.stockbloghub.com/tag/agree-realty-corporation/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Beats by a Penny</title>
		<link>http://www.stockbloghub.com/2009/10/22/bmy-bristol-myers-squibb-company-beats-by-a-penny/18527</link>
		<comments>http://www.stockbloghub.com/2009/10/22/bmy-bristol-myers-squibb-company-beats-by-a-penny/18527#comments</comments>
		<pubDate>Thu, 22 Oct 2009 22:27:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADC]]></category>
		<category><![CDATA[Agree Realty Corporation]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18527</guid>
		<description><![CDATA[This morning, Bristol-Myers Squibb Company (BMY) reported third quarter earnings of 52 cents per share, beating the Zacks Consensus Estimate by a penny. The company reported earnings of 45 cents in the year-ago period. Net sales for the quarter came in at $5,487 million, against $5,254 million in the year-ago quarter, thus representing an increase of 4.4%. It comprised $4,788 million in pharmaceutical product sales, up 6%, and $699 million in Nutritional sales, down 6%. Growth in the pharmaceutical division was driven by strong sales of Plavix at $1,554 million, up 8%, HIV medication Sustiva at $315 million, up 7% and hepatitis B drug Baraclude at $191 million, up 33%, Schizophrenia drug Abilify came in at $653 million, up 16%, rheumatoid arthritis drug Orencia was at $162 million, up 36% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/22/bmy-bristol-myers-squibb-company-beats-by-a-penny/18527/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

